EuroSCORE II and the STS score are more accurate in transapical than in transfemoral transcatheter aortic valve implantation. (27th October 2017)

• Record Type: Journal Article
• Authors: Kofler, Markus; Reinstadler, Sebastian J; Stastny, Lukas; Dumfarth, Julia; Reindl, Martin; Wachter, Kristina; Rustenbach, Christian J; Müller, Silvana; Feuchtner, Gudrun; Friedrich, Guy; Metzler, Bernhard; Grimm, Michael; Bonaros, Nikolaos; Baumbach, Hardy
• Is Part Of: Interactive cardiovascular and thoracic surgery. Volume 26:Number 3(2018)
• Page Start: 413
• Page End: 419
• Publication Date: 2017-10-27
• Subjects: Risk prediction in transcatheter aortic valve implantation -- European System for Cardiac Operative Risk Evaluation II -- Society of Thoracic Surgeons score -- Transcatheter aortic valve implantation -- Access site; Chest -- Surgery -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.1
• DOI: 10.1093/icvts/ivx343
• Languages: English
• ISSNs: 1569-9293

Abstract

Abstract: OBJECTIVES: The European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and the Society of Thoracic Surgeons (STS) score are currently used to estimate periprocedural risk of death in patients undergoing transcatheter aortic valve implantation (TAVI). However, data regarding the predictive ability and usefulness of these scores for TAVI are controversial, especially for different access sites. METHODS: Between 2008 and 2016, 1192 consecutive patients undergoing TAVI [transfemoral (TF): n = 607 (51%); transapical (TA): n = 585 (49%)] at 2 centres were included. All-cause mortality was assessed at a median of 533 days (interquartile range 153–1036). The value of the EuroSCORE II and the STS score in terms of predicting 30-day and cumulative mortality according to access site was investigated. RESULTS: The mean age was 83 (interquartile range 79–86) years. Overall, the 30-day mortality rate was 7.6% ( n = 90), and the cumulative all-cause mortality rate was 35.1% ( n = 418). The EuroSCORE II and the STS score were significantly increased in non-survivors compared with survivors ( P < 0.001). The EuroSCORE II and the STS score emerged as independent predictors of 30-day mortality [EuroSCORE II: odds ratio (OR) 1.039, 95% confidence interval (CI) 1.013–1.065; P = 0.003; STS score: OR 1.055, 95% CI 1.023–1.088; P = 0.001] and cumulative all-cause mortality [EuroSCORE II: hazard ratio (HR) 1.026, 95% CI 1.013–1.038; P < 0.001; STS score: HR 1.05, 95% CI 1.03–1.06; P < 0.001]. In contrast to TF TAVI, the EuroSCORE II (OR 1.038, 95% CI 1.009–1.068; P = 0.010) and the STS score (OR: 1.063, 95% CI 1.025–1.102; P = 0.001) were independent predictors of 30-day mortality and cumulative mortality (EuroSCORE II: HR 1.023, 95% CI 1.009–1.037; P = 0.001; STS score: HR 1.055, 95% CI 1.037–1.073; P < 0.001) in patients undergoing TA TAVI. CONCLUSIONS: The EuroSCORE II and the STS score were independent predictors of 30-day and cumulative mortality rates in patients undergoing TAVI. The EuroSCORE II and the STS score were associated with 30-day mortality and mortality during follow-up period only in TA TAVI.